A Study Evaluating AMG 451 in Moderate To-severe Atopic Dermatitis (ROCKET-IGNITE)

Status:
Not yet recruiting

Trial end date:
2025-01-05

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of AMG 451 in monotherapy treatment.

Phase 3

Amgen